NCT02410135View on ClinicalTrials.gov

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Lower Urinary Tract SymptomsNocturia
Interventions
DRUG

Mirabegron

25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks

Trial Locations (1)

62794-9665

SIUSOM - Division of Urology, Springfield

All Listed Sponsors
collaborator

Astellas Scientific & Medical Affairs, Inc.

INDUSTRY

collaborator

Sisters of the Third Order of St. Francis

OTHER

lead

Southern Illinois University

OTHER

NCT02410135 - Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS) | Biotech Hunter | Biotech Hunter